Vinca Alkaloid is a type of drug that blocks cell growth by stopping mitosis (cell division). Vinca alkaloids interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A vinca alkaloid is a type of mitotic inhibitor and antimicrotubule agent.
Using practical nano-DDS technology, a polymeric nanomicelle that effectively delivers the potent mitotic inhibitor desacetyl vinblastine hydrazide (DAVBNH) to glioblastoma (GBM) was developed.
A group of Moscow scientists has discovered and explained the activity mechanism of a new anti-cancer molecule -- diphenylisoxazole.
Vinorelbine Bitartrate, a semi-synthetic vinca alkaloid was approved by the FDA for breast cancer treatment, as it has been proven to be beneficial for first line of defense and subsequent therapies. But its hydrophilic and thermolabile structure causes hindrance to oral clinical translation.
An international team of scientists, including MIPT researchers, has defined the way their promising anti-cancer molecules work.
Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.
Merck, known as MSD outside the United States and Canada, and Endocyte Inc., today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145).
A new strategy that takes advantage of ovarian cancer's reliance on folate appears to give relapse patients extra months of life with few side effects, researchers say.
GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.
A chemotherapy regimen for patients with advanced bladder cancer who aren't eligible for standard treatment is under study at the Medical College of Georgia.
Integrating the use of drugs targeted to specific cancer proteins into current chemotherapy regimens to improve the efficacy of systemic treatment is an important clinical goal at Fox Chase Cancer Center.